Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2 having the formula I: Also provided are methods of inhibiting ROCK1 and/or ROCK2 useful for the treatment of disease.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
March 12, 2024
Assignee:
Kadmon Corporation, LLC
Inventors:
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
Abstract: The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients and modifying the administration based on the results of such identification.
Abstract: The present disclosure relates to the co-administration of Belumosudil with CYP3A Inducers and/or Proton Pump Inhibitors for use in the treatment of subjects with chronic graft-versus-host disease (cGVHD).
Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.
Abstract: Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.
Type:
Application
Filed:
June 23, 2021
Publication date:
December 28, 2023
Applicant:
Kadmon Corporation, LLC
Inventors:
Dan Lu, Zhanna Polonskaya, Tzu-Pei Chang, Stella Aviaty Martomo, Jeegar P. Patel, Faical Miyara
Abstract: The present disclosure relates generally to the treatment of patients with chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation by administering belumosudil at certain dosages.
Type:
Application
Filed:
April 18, 2023
Publication date:
November 30, 2023
Applicant:
Kadmon Corporation, LLC
Inventors:
Sanjay Aggarwal, Mark Berger, David Eiznhamer, Jeegar P. Patel, Olivier Schueller
Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
Abstract: Provided herein are recombinant antibodies, antigen-binding fragments thereof, and fusion proteins thereof useful for binding to and inhibiting B7-H4. Also provided are nucleic acid molecules encoding the antibodies, antigen-binding fragments thereof, and fusion proteins thereof disclosed herein and therapeutic compositions thereof. Disclosed are further methods of using the disclosed antibodies, antigen-binding fragments thereof, and fusion proteins thereof for the treatment of disease.
Type:
Application
Filed:
November 29, 2022
Publication date:
October 5, 2023
Applicant:
Kadmon Corporation, LLC
Inventors:
Dan Lu, Jeegar P. Patel, Tzu-Pei Chang, Zhanna Polonskaya, Faical Miyara
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
Type:
Application
Filed:
February 1, 2023
Publication date:
June 8, 2023
Applicant:
Kadmon Corporation, LLC
Inventors:
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo
Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
March 28, 2023
Assignee:
Kadmon Corporation, LLC
Inventors:
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of inhibiting ROCK1 and/or ROCK2 that are useful for the treatment of disease.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
October 25, 2022
Assignee:
Kadmon Corporation, LLC
Inventors:
Eduardas Skucas, Kevin G. Liu, Ji-In Kim, Masha V. Poyurovsky, Rigen Mo, Jingya Zhang
Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.
Type:
Grant
Filed:
April 9, 2015
Date of Patent:
April 26, 2022
Assignees:
KADMON CORPORATION, LLC, REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventors:
Alexandra Zanin-Zhorov, Bruce Robert Blazar, Ryan Flynn
Abstract: This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake. In particular aspects, the present invention provides a method of treating inflammatory conditions and autoimmune diseases in a mammal, and preferably a human, in which the glucose uptake inhibitor modulates the glucose transport of GLUT1 and GLUT3.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
July 27, 2021
Assignee:
KADMON CORPORATION, LLC
Inventors:
Ji-In Kim, Kellen L. Olszewski, Anthony M. Barsotti, Masha V. Poyurovsky, Kevin G. Liu, Koi Morris, Xuemei Yu
Abstract: Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and the known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: wherein the variables have the values disclosed herein.
Type:
Grant
Filed:
April 29, 2019
Date of Patent:
April 27, 2021
Assignee:
Kadmon Corporation, LLC
Inventors:
Kellen L. Olszewski, Ji-In Kim, Masha V. Poyurovsky, Kevin G. Liu, Anthony Barsotti, Koi Morris
Abstract: Provided are methods of treating infectious diseases in mammals comprising administering a compound that inhibits glucose uptake. Particular infectious diseases that may be treated include malaria, leishmaniasis, African trypanosomiasis, tuberculosis, HIV, HCMV or herpes virus. In a first aspect, the invention features a method of treating infectious diseases in a mammal, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug, wherein the compound is an inhibitor of glucose uptake.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
August 4, 2020
Assignee:
KADMON CORPORATION, LLC
Inventors:
Kellen Olszewski, Masha Poyurovsky, Anthony Barsotti, Ji-Ln Kim, Kevin G. Liu
Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
June 30, 2020
Assignee:
Kadmon Corporation, LLC
Inventors:
Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.